# A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)

> **NCT02417597** · PHASE4 · COMPLETED · sponsor: **Xiamen Innovax Biotech Co., Ltd** · enrollment: 600 (actual)

## Conditions studied

- Hepatitis E

## Interventions

- **BIOLOGICAL:** Recombinant Hepatitis E Vaccine (Escherichia Coli)

## Key facts

- **NCT ID:** NCT02417597
- **Lead sponsor:** Xiamen Innovax Biotech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04
- **Primary completion:** 2016-05
- **Final completion:** 2016-05
- **Target enrollment:** 600 (ACTUAL)
- **Last updated:** 2016-05-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02417597

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02417597, "A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02417597. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*